ERBB2 and breast cancer: Hence, we hypothesize that the over-activation of HER2, reflected by the over-phosphorylation at position Y877 of the receptor, could be recognized by trastuzumab, and that HER2 phosphorylation could be biologically more relevant than simple protein overexpression in BC diagnosis.